{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T21:48:58Z","timestamp":1781300938835,"version":"3.54.1"},"reference-count":15,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Case Rep Oncol"],"abstract":"<jats:p>Introduction: Treatment strategies for metastatic renal cell carcinoma (mRCC) have advanced, and its prognosis has improved. However, the progression-free survival of patients with mRCC who have received prior treatment is approximately 8 months, and long-term responses are rare. We applied therapeutic drug monitoring to a case of mRCC in which a long-term response of more than 3 years was achieved after the administration of cabozantinib as third-line treatment. Here, we report the changes in the blood concentration of cabozantinib. Case Presentation: The patient was a 67-year-old man who had received sunitinib as the first-line treatment and nivolumab as the second-line treatment for stage IV mRCC. However, the disease progressed, and cabozantinib (40 mg\/day) was initiated. Three months after the initiation of cabozantinib, partial tumor shrinkage was achieved. In the sixth month, the dose was reduced to 20 mg\/day because of severe palmar-plantar erythrodysesthesia syndrome and anorexia; however, further tumor shrinkage was achieved. Fifteen months after starting cabozantinib, the trough concentration of cabozantinib was 960 ng\/mL. Thereafter, cabozantinib concentration was measured almost every month and was found to fluctuate between 583 and 1,938 ng\/mL; tumor shrinkage was maintained even at 39 months. Conclusion: Cabozantinib provided long-term benefits for more than 3 years. We emphasize that the measurement of cabozantinib concentration in the blood may play a supporting role as an indicator of long-term response. <\/jats:p>","DOI":"10.1159\/000545249","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T17:24:16Z","timestamp":1742491456000},"page":"500-507","source":"Crossref","is-referenced-by-count":2,"title":["Therapeutic Drug Monitoring in a Patient with Metastatic Renal Cell Carcinoma Who Achieved Long-Term Response to Cabozantinib in Third-Line Treatment: A Case Report"],"prefix":"10.1159","volume":"18","author":[{"given":"Shinichi","family":"Maruyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuru","family":"Hiraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0001"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(11)61613-9"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510016"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510665"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.503"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.5599"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2021.03.001"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/iju.15206"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10102444"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.3087"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100312"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/iju.14329"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/ph15121460"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-0439"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16213689"}],"container-title":["Case Reports in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000545249","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000545249","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T16:01:43Z","timestamp":1745856103000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000545249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000545249","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.28615994","asserted-by":"subject"}]},"ISSN":["1662-6575"],"issn-type":[{"value":"1662-6575","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,20]]}}}